GSTM1 and myelodysplastic syndrome: A randomized, blinded trial of darbepoetin alfa in 147 LR‐MDS patients with Hb <10 g/dL and sEPO <500 iu/L reported a haematological improvement of 14.7%, compared to 0% in the placebo group (p = 0.02).36